It’s crucial to underscore that while inhibiting CtBP2, p300, or NF-κB demonstrated improved inflammatory symptoms in ARDS mice models, it also unveiled the onset of side effects attributed to the alteration in the expressions of other target genes, emphasizing the need for precise therapeutic interventions. Here, CTBP2 is linked to acute respiratory distress syndrome.